LYCOFER

This brand name is authorized in Nigeria

Active ingredients

The drug LYCOFER contains a combination of these active pharmaceutical ingredients (APIs):

1 Sodium feredetate
UNII 403J23EMFA - SODIUM FEREDETATE

Sodium feredetate is used for iron deficiency anaemia. After absorption, elemental iron is available for haemoglobin regeneration and reversal of anaemia associated with iron-deficient states.

Read about Sodium feredetate
2 Folic acid
UNII 935E97BOY8 - FOLIC ACID

Folic acid is a member of the vitamin B group which is reduced in the body to tetrahydrofolate, a co-enzyme active in several metabolic processes and produces a haemopoietic response in nutritional megaloblastic anaemias. Folic acid is rapidly absorbed and widely distributed in body tissues.

Read about Folic acid
3 Vitamin B12
UNII P6YC3EG204 - CYANOCOBALAMIN

Hydroxocobalamin is used in the treatment and prevention of Vitamin B12 deficiency. For adults, the daily requirement of Vitamin B12 is probably about 1 to 2 micrograms and this amount is present in most normal diets. However, Vitamin B12 only occurs in animal products, not in vegetables, and therefore strict vegetarian or vegan diets that exclude dairy products may provide an inadequate amount, although a deficiency may not be apparent for many years.

Read about Vitamin B12
4 Zinc
UNII J41CSQ7QDS - ZINC

Zinc blocks the intestinal absorption of copper from the diet and the reabsorption of endogenously secreted copper. Zinc induces the production of metallothionein in the enterocyte, a protein that binds copper thereby preventing its transfer into the blood. The bound copper is then eliminated in the stool following desquamation of the intestinal cells.

Read about Zinc

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
B03AE01 Iron, vitamin B12 and folic acid B Blood and blood forming organs → B03 Antianemic preparations → B03A Iron preparations → B03AE Iron in other combinations
Discover more medicines within B03AE01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: NG Registered Drug Product Database Identifier(s): A4-5049, A4-5064

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.